About Avizorex Pharma
Avizorex Pharma is a company based in Barcelona (Spain) founded in 2013 by Carlos Belmonte was acquired by Aerie Pharma in November 2019.. Avizorex Pharma has raised $3.16 million across 2 funding rounds from investors including EIT Health, Aerie Pharma and Inveready. Avizorex Pharma offers products and services including Avanafil, Cialis Genérico, Viagra Genérico, Amoxil, and Lamictal. Avizorex Pharma operates in a competitive market with competitors including Oyster Point Pharmaceuticals, Remegen, Retrotope, Biophytis and Azura Ophthalmics, among others.
- Headquarter Barcelona, Spain
- Founders Carlos Belmonte
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$3.16 M (USD)
in 2 rounds
-
Latest Funding Round
$57.33 K (USD), Grant
Jul 18, 2017
-
Investors
EIT Health
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Aerie Pharma
(Nov 18, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Avizorex Pharma
Avizorex Pharma offers a comprehensive portfolio of products and services, including Avanafil, Cialis Genérico, Viagra Genérico, Amoxil, and Lamictal. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Medication for treating erectile dysfunction and related conditions.
Generic drug for improving erectile function in patients.
Prescription medicine for erectile dysfunction management.
Antibiotic used to treat bacterial infections effectively.
Medication for controlling seizures and epilepsy symptoms.
Funding Insights of Avizorex Pharma
Avizorex Pharma has successfully raised a total of $3.16M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $57.33 thousand completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $57,330
-
First Round
First Round
(13 Oct 2014)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2017 | Amount | Grant - Avizorex Pharma | Valuation |
investors |
|
| Oct, 2014 | Amount | Series A - Avizorex Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Avizorex Pharma
Avizorex Pharma has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include EIT Health, Aerie Pharma and Inveready. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare startups are accelerated and incubated through specialized programs.
|
Founded Year | Domain | Location | |
|
Inveready is recognized as a leading Spanish financial services firm.
|
Founded Year | Domain | Location | |
|
Therapies for glaucoma, dry eye, and retinal diseases are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Avizorex Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Avizorex Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Avizorex Pharma Comparisons
Competitors of Avizorex Pharma
Avizorex Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oyster Point Pharmaceuticals, Remegen, Retrotope, Biophytis and Azura Ophthalmics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene therapies for ophthalmological diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for cancer, autoimmune, and eye diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurodegenerative and ophthalmological diseases are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for neuromuscular and age-related diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developing therapies for meibomian gland dysfunction
|
|
| domain | founded_year | HQ Location |
Topical therapeutics for the treatment of dry eye disease
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Avizorex Pharma
When was Avizorex Pharma founded?
Avizorex Pharma was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Where is Avizorex Pharma located?
Avizorex Pharma is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Is Avizorex Pharma a funded company?
Avizorex Pharma is a funded company, having raised a total of $3.16M across 2 funding rounds to date. The company's 1st funding round was a Series A of $3.16M, raised on Oct 13, 2014.
What does Avizorex Pharma do?
Avizorex Pharma was established in 2013 in Barcelona, Spain, within the pharmaceutical sector. Focus is placed on developing treatments for dry eye disease, with AVX-012 advancing through Phase II clinical trials. Neural mechanisms that control tear fluid secretion from lacrimal glands are targeted, as are sensations of discomfort arising from ocular surface dryness. Operations center on innovative drug candidates for this condition.
Who are the top competitors of Avizorex Pharma?
Avizorex Pharma's top competitors include Remegen, Lineage Cell Therapeutics and Oyster Point Pharmaceuticals.
What products or services does Avizorex Pharma offer?
Avizorex Pharma offers Avanafil, Cialis Genérico, Viagra Genérico, Amoxil, and Lamictal.
Who are Avizorex Pharma's investors?
Avizorex Pharma has 3 investors. Key investors include EIT Health, Aerie Pharma, and Inveready.